Skip to main content Accessibility help

Psychopathology, insight and compliance in schizophrenia

  • Vikrant Bajaj (a1), Somnath Sengupta (a2) and Dhanesh Kumar Gupta (a2)


Objective: A four-week longitudinal study was conducted to assess the relationship between insight, psychopathology and treatment compliance in schizophrenia.

Method: The study was conducted using Insight and Treatment Attitude Questionnaire (ITAQ), Positive and Negative Syndrome Scale (PANSS) and Medication Adherence Rating Scale (MARS). The sample comprised 50 patients with schizophrenia diagnosed according to research criteria of the International Classification of Diseases (ICD-10), with a mean duration of illness of 5.32 years.

Results: Substantial psychopathology was observed at intake and it improved significantly at the end of four weeks. Similar changes were observed in the score of insight and of compliance over four weeks. The insight and the compliance were positively correlated to each other at the beginning and at the end of four weeks. Both of these were negatively correlated with psychopathology scores on both occasions.

Conclusion: Insight and psychopathology remain important determinants of treatment compliance in schizophrenia over short term and long term follow up.


Corresponding author

*Correspondence Email:


Hide All
1.Fenton, WS, Blyler, CR. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schiz Bull 1997; 23(4): 637651.
2.Robinson, D, Woerner, MG. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999; 56: 241247.
3.Jeffreys, SE, Harvey, CA. The Hampstead Schizophrenia Survey 1991: prevalence and service use comparisons in an inner London health authority, 1986-1991. Br J Psychiatry 1997; 170: 301306.
4.Adams, J, Scott, J. Predicting medication adherence in severe mental disorders. Acta Psychiatr Scand 2000; 101: 119124.
5.McCabe, R, Quayle, E. Is there a role for compliance in the assessment of insight in chronic schizophrenia? Psychology, health and medicine 2000; 5(2):173178.
6.McEvoy, JP, Freter, S. Insight and clinical outcome of schizophrenic patients. J Nerv MentDis 1989; 177:4851.
7.Cuffel, BJ, Alford, J. Awareness of illness in schizophrenia and outpatient treatment adherence. J Ner Ment Dis 1996; 184(11): 653659.
8.Rittmannsberger, H, Pachinger, T. Medication adherence among psychotic patients before admission to inpatient treatment. Psychiatr Serv 2004; 55: 174179.
9.Marder, SR, Mebane, A. A comparison of patients who refuse and consent to neuroleptic treatment. Am J Psychiatry 1983;140: 470472.
10.Verdoux, H, Lengronne, J. Medication adherence in psychosis: predictors and impact on outcome. A 2 year follow up of first admitted subjects. Acta Psychiatr Scand 2000; 102:203210
11.David, A, Buchanan, A, Reed, A. The assessment of insight in psychosis. Br J Psychiatry 1992; 161: 599602.
12.World Health Organization. The ICD-10 classification of mental and behavioural disorders: Clinical descriptions and diagnostic guidelines. Geneva, World Health Organization, 1992.
13.McEvoy, JP, Apperson, IJ. Insight in schizophrenia: its relationship to acute psychopathology. J Nerv Ment Dis 1989; 177: 4347.
14.Kay, SR, Fiszbein, A, Opler, LA. The positive and negative syndrome scale for schizophrenia. Schizophr Bull 1987; 13: 261276.
15.Thompson, K, Kulkarni, J. Reliability and validity of a new medication adherence rating scale for the psychoses. Schizophr Res 2000; 102: 241247.
16.Kulhara, P, Chakravarty, S, Basu, D. Insight and psychosis: An empirical enquiry. Ind J Soc Psychiatry 1992; 8: 4044.
17.Trauer, T, Sacks, T. The relationship between insight and medication adherence in severely mentally ill clients treated in community. Acta Psychiatr Scand 2000; 102: 211216.
18.Lincoln, AKP, Chandrasekharan, R. Insight, psychopathology and schizophrenia. Ind J Psychiatry 2002; 44(4): 332336.
19.Heinrichs, DW, Cohen, BP, Carpenter, WT. Early insight and the management of schizophrenic decompensation. J Nerv Ment Dis 1985; 173(3): 133138.
20.Amador, XF, Strauss, DH. The assessment of insight in psychosis. Am J Psychiatry 1993; 150:873879.
21.Cuesta, MJ, Peralta, V. Lack of insight in schizophrenia. Schizophr Bull 1994; 20(2): 359366.
22.Aga, VM, Agarwal, AK, Gupta, SC. The relationship of insight to psychopathology in schizophrenia. Ind J Psychiatry 1995; 37(3): 129135.
23.Tattan, TMG, Creed, FH. Negative symptoms of schizophrenia and compliance with medication. Schizophr Bull 2001; 27(1): 149155.
24.Mehrotra, S, Sengupta, SN. Insight and psychopathology in schizophrenia: A four week longitudinal study. German J Psychiatry 2005; 8: 4852.
25.Lin, IF, Spiga, R. Insight and adherence to medication in chronic schizophrenia. J Clin Psychiatry 1979; 40(10): 430432.
26.Tharyan, A, Saravanan, B. Insight and psychopathology in schizophrenia. Ind J Psychiatry 2000; 42(4): 421426.
27.Saravanan, B, Jacob, KS. Assessing insight in schizophrenia: East meets west. Br J Psychiatry 2007; 190: 243247.
28.Bartko, G, Hertzeg, I, Zador, G. Clinical symptomatology and drug compliance in schizophrenic patients. Acta Psychiatr Scand 1988; 77: 7476.
29.Dervaux, A, Bayle, FJ, Laqueille, Xet al.Nicotine use in schizophrenia and disinhibition. Psychiatry Res 2004; 128(3): 229234.


Psychopathology, insight and compliance in schizophrenia

  • Vikrant Bajaj (a1), Somnath Sengupta (a2) and Dhanesh Kumar Gupta (a2)


Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed